Jaguar Health Compliant with Nasdaq Bid Price Rule

Jaguar Health (NASDAQ:JAGX) reported that Nasdaq notified the company on May 26, 2026 that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the Bid Price Rule, and its securities remain listed and traded.

Rhea-AI Impact

(High)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) reported that Nasdaq notified the company on May 26, 2026 that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the Bid Price Rule, and its securities remain listed and traded.

Q1 2026 net revenue increased 816% year-over-year and 527% sequentially, supported by a US out-license agreement with Future Pak for Mytesi and Canalevia-CA1. Jaguar is focusing on its pivotal-stage crofelemer program for rare intestinal failure, targeting an NDA in mid-2027 and seeking a development and commercialization partner.

Positive

Regained compliance with Nasdaq Bid Price Rule 5550(a)(2)
Securities continue to be listed and traded on Nasdaq
Q1 2026 net revenue increased 816% versus Q1 2025
Q1 2026 net revenue increased 527% versus Q4 2025
US out-license agreement with Future Pak for Mytesi and Canalevia-CA1
NDA for crofelemer formulation targeting mid-2027

Argus May 27 session

+2.57% close to close Open Argus

Details

News Market Reaction – JAGX

On May 27, the day this news came out, JAGX closed 2.57% above the previous close.

Data tracked by StockTitan Argus for the May 27 session.

Market Context

This announcement confirms Jaguar has regained compliance with Nasdaq’s bid price rule, preserving i...

Analysis

This announcement confirms Jaguar has regained compliance with Nasdaq’s bid price rule, preserving its exchange listing. Management also highlights Q1 2026 net revenue growth of 816% year over year and 527% sequentially, driven by a U.S. out-license agreement, and targets an NDA for crofelemer in mid-2027. Against a backdrop of complex recent financings and a stock price 98.01% below its 52-week high, investors may watch ongoing Nasdaq compliance, licensing cash flows, and pivotal trial progress closely.

Key Figures

Net revenue growth YoY: 816% Sequential revenue growth: 527% Quarter referenced: Q1 2026 +5 more

Net revenue growth YoY: 816%; Q1 2026 vs Q1 2025 net revenue change referenced in release
Sequential revenue growth: 527%; Q1 2026 vs Q4 2025 net revenue change
Quarter referenced: Q1 2026; Compared against Q1 2025 and Q4 2025 in release
Prior quarter: Q4 2025; Baseline for sequential revenue comparison
NDA timing target: mid-2027; Targeted NDA submission for crofelemer powder formulation
Price move pre-news: 6.87%; 24h price change before this Nasdaq compliance announcement
52-week high distance: 98.01%; Price trading below 52-week high
52-week low distance: 22.92%; Price trading above 52-week low

Historical Context

5 past events · Latest: May 20

5 events

May 20
Q1 2026 earnings

24h Move

-5.5%

Massive revenue jump from licensing deal and improved operating results.
May 20
Investor webcast notice

24h Move

+2.8%

Announcement of webcast and conference presentation on Q1 results and updates.
May 19
Clinical trial update

24h Move

-9.3%

Continuation phase of pivotal pediatric MVID crofelemer trial to support NDA.
May 8
Nasdaq compliance/status

24h Move

+0.7%

Regained compliance with publicly held shares and extension for bid-price rule.
May 6
Regulatory discussion

24h Move

-6.3%

Preliminary FDA discussion on potential Breakthrough Therapy Designation.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

out-license agreement, pivotal-stage development program, nda

3 terms

out-license agreement financial

"buoyed by the US out-license agreement we executed with Future Pak"

An out-license agreement is a contract where a company grants another firm the right to develop, manufacture or sell a specific product or technology in defined territories or uses, while keeping ownership of the underlying intellectual property. For investors it matters because such deals can bring upfront payments, milestone fees and ongoing royalties, lower development costs and risk, and help a product reach markets faster — think of it like renting out a proven idea to a partner who has the tools to make and sell it.

pivotal-stage development program medical

"We continue to sharply focus on our pivotal-stage development program"

A pivotal-stage development program is the late, decisive phase of testing for a drug or medical product when large studies are run specifically to provide the evidence regulators need to decide on approval. It matters to investors because success at this stage is the main trigger that shifts a product from experimental to potentially marketable, greatly affecting a company’s value, future revenue prospects, and capital needs — like a final inspection that clears a building for occupancy.

nda regulatory

"rare intestinal failure indications, targeting an NDA in mid-2027"

An NDA, or nondisclosure agreement, is a legal contract that keeps certain information private between parties. It’s like a promise not to share sensitive details, helping protect business ideas, strategies, or data from being leaked or used without permission. For investors, NDAs help ensure that confidential information remains secure, enabling trust and open communication during business discussions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

05/27/2026 - 09:00 AM

JAGX's securities continue to be listed and traded on Nasdaq

SAN FRANCISCO, CA / ACCESS Newswire / May 27, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on May 26, 2026, the Company received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") that Jaguar has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule").

"We are very happy that Jaguar has regained compliance with the Nasdaq listing criteria. We consider our Nasdaq listing an asset of the Company," said Lisa Conte, Jaguar's president and CEO. "As we were pleased to report on May 20, 2026, Jaguar's net revenue increased 816% in Q1 2026 versus Q1 2025, and increased 527% in Q1 2026 over the previous quarter, Q4 2025, buoyed by the US out-license agreement we executed with Future Pak for Mytesi and Canalevia-CA1 this past January. We continue to sharply focus on our pivotal-stage development program for our novel proprietary powder-for-oral-solution formulation of crofelemer for rare intestinal failure indications, targeting an NDA in mid-2027, and on identifying a development and commercialization partner for this program."

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

hello@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Jaguar Health (NASDAQ:JAGX) announce about Nasdaq bid price compliance on May 27, 2026?

Jaguar Health announced it regained compliance with Nasdaq Listing Rule 5550(a)(2), the Bid Price Rule. According to Jaguar Health, its securities continue to be listed and traded on Nasdaq after Nasdaq issued formal notice on May 26, 2026.

How did Jaguar Health's net revenue change in Q1 2026 versus Q1 2025 (JAGX)?

Jaguar Health reported that Q1 2026 net revenue increased 816% compared with Q1 2025. According to Jaguar Health, this growth was buoyed by a US out-license agreement with Future Pak for Mytesi and Canalevia-CA1 executed in January 2026.

What was Jaguar Health's sequential net revenue growth in Q1 2026 versus Q4 2025?

Jaguar Health stated that Q1 2026 net revenue increased 527% over Q4 2025. According to Jaguar Health, the strong sequential growth was supported by the US out-license agreement with Future Pak for Mytesi and Canalevia-CA1 signed earlier in the year.

What is Jaguar Health's development focus for its crofelemer powder formulation?

Jaguar Health is focusing on a pivotal-stage development program for a crofelemer powder-for-oral-solution formulation. According to Jaguar Health, this program targets rare intestinal failure indications and aims for submission of a New Drug Application (NDA) around mid-2027.

How does the Future Pak out-license agreement affect Jaguar Health (JAGX)?

Jaguar Health linked recent revenue growth to its US out-license agreement with Future Pak for Mytesi and Canalevia-CA1. According to Jaguar Health, Q1 2026 net revenue increases of 816% year-over-year and 527% sequentially were buoyed by this January 2026 agreement.

What partnership plans does Jaguar Health have for its rare intestinal failure program?

Jaguar Health is seeking a development and commercialization partner for its crofelemer formulation targeting rare intestinal failure. According to Jaguar Health, this effort complements its focus on the pivotal-stage program and its goal of filing an NDA by mid-2027.

Jaguar Health Compliant with Nasdaq Bid Price Rule